Last Updated : July 27, 2024
The latest Reimbursement Review reports are posted to this page. Our Reimbursement Reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
Brand Name Sort descending | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
---|---|---|---|---|---|---|
Brivlera | Brivaracetam | Epilepsy, partial-onset seizures | Reimburse with clinical criteria and/or conditions | Complete | ||
Brukinsa | zanubrutinib | Mantle cell lymphoma (MCL) | Do not reimburse | Complete | ||
Brukinsa | zanubrutinib | Chronic lymphocytic leukemia /small lymphocytic lymphoma. | Reimburse with clinical criteria and/or conditions | Complete | ||
Brukinsa | zanubrutinib | Relapsed or refractory follicular lymphoma | Canada’s Drug Agency is unable to recommend reimbursement as a submission was not filed by the manufacturer | Not filed | ||
Brukinsa | zanubrutinib | Waldenström’s macroglobulinemia | Reimburse with clinical criteria and/or conditions | Complete | ||
BuTrans | Buprenorphine transdermal patch | Pain, persistent (moderate intensity) | Cancelled | |||
BuTrans | Buprenorphine transdermal patch | Pain, moderate intensity persistent pain | Do not list | Complete | ||
Byetta | Exenatide | Diabetes mellitus, type 2 | Do not list | Complete | ||
Bylvay | odevixibat | Progressive familial intrahepatic cholestasis (PFIC) | Reimburse with clinical criteria and/or conditions | Complete | ||
Bystolic | Nebivolol | Hypertension | Do not list at the submitted price | Complete |